Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III heparan sulfate versus placebo in primary chronic venous disease
2024-514679-16-00Phase 3Authorised
- Sponsor
- Farmaceutici Damor
- Start
- Oct 2026
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic venous disease (CVD) comparing Heparan sulfate with Placebo (2 arms). Primary endpoint: Change in Revised Venous Clinical Severity Score. Planned start Oct 2026; status: authorised.
02
Drugs
heparan sulfate
03
Conditions
chronic venous disease (CVD)
Beyond the preview
Go deeper on 2024-514679-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514679-16-00.